Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma
Open Access
- 8 August 2005
- journal article
- research article
- Published by Elsevier BV in Annals Of Oncology
- Vol. 16 (11), 1824-1828
- https://doi.org/10.1093/annonc/mdi362
Abstract
Background: Magnetic resonance imaging (MRI) has been a useful technique for the assessment of patients with multiple myeloma (MM). We evaluated the prognostic significance of different MRI patterns in symptomatic patients with MM. Patients and methods: A total of 142 symptomatic MM patients underwent MRI before treatment. MRI patterns of involvement were correlated with known prognostic variables, including the International Staging System (ISS), response to treatment and survival. Results: Focal marrow lesions were identified in 50% of patients, diffuse marrow replacement in 28%, a variegated pattern in 14% and normal pattern in 8%. When patients with the diffuse pattern were compared with patients with the other MRI patterns, they had features of more advanced disease such as higher ISS, anemia, hypercalcemia, elevated lactate dehydrogenase and extensive marrow plasmacytosis. Response rate was similar among patients with different MRI patterns. Median survival was 24 months for patients with the diffuse pattern, 51 months for those with the focal pattern, 52 months for those with the variegated pattern and 56 months for patients with the normal pattern (P = 0.001). The presence or absence of a diffuse MRI pattern separated patients with ISS stages I and II into two subgroups with significantly different survival times of 28 months and 61 months, respectively (P = 0.01). Furthermore, a diffuse MRI pattern predicted inferior outcome regardless of whether or not patients had received high-dose therapy with autologous stem cell transplantation. Conclusion: Diffuse marrow replacement on MRI adds to the evaluation of patients with multiple myeloma and their management.This publication has 24 references indexed in Scilit:
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005
- Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myelomaAnnals Of Oncology, 2003
- Imaging of Myeloma Bone Disease - Implications for Staging, Prognosis and Follow-upActa Oncologica, 2000
- HyperCVAD for VAD-resistant multiple myelomaAmerican Journal of Hematology, 1996
- Limited value of myeloablative therapy for late multiple myelomaBlood, 1994
- Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myelomaBlood, 1993
- Multiple myeloma: spinal MR imaging in patients with untreated newly diagnosed disease.Radiology, 1992
- VAD‐based regimens as primary treatment for multiple myelomaAmerican Journal of Hematology, 1990
- The prognostic significance of X‐ray changes at presentation and reassessment in patients with multiple myelomaHematological Oncology, 1988
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survivalCancer, 1975